Upstream Bio (UPB) Capital Expenditures (2024 - 2025)
Upstream Bio's (UPB) quarterly Capital Expenditures came in at $110000.0 in Q4 2025, down 70.9% year-on-year from $378000.0 in Q4 2024, and up 1275.0% quarter-over-quarter from $8000.0 in Q3 2025.
Upstream Bio (UPB) Capital Expenditures (2024 - 2025) Analysis & Trends
Upstream Bio's Capital Expenditures history runs 2 years deep, the most recent figure standing at $110000.0 for Q4 2025.
- On a quarterly basis, Capital Expenditures fell 70.9% year-over-year to $110000.0 in Q4 2025; TTM through Dec 2025 was $496000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $165000.0, down 67.71% from the prior year.
- Capital Expenditures rose to $110000.0 in Q4 2025 per UPB's latest filing, from $8000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $378000.0 in Q4 2024 and bottomed at $8000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Upstream Bio | 347.73 Mn | 347.73 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110,000.00 |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Dec 31, 2024 | 378,000.00 |